Study of M5049 in DM and PM Participants (NEPTUNIA)
Status:
Not yet recruiting
Trial end date:
2024-12-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of orally administered M5049
in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis
(PM) participants for 24 weeks.